Affordable Access

APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial.

Authors
  • Wimmer, Robert S
  • Chauvenet, Allen R
  • London, Wendy B
  • Villaluna, Doojduen
  • de Alarcon, Pedro A
  • Schwartz, Cindy L
Type
Published Article
Journal
Pediatric blood & cancer
Publication Date
Mar 01, 2006
Volume
46
Issue
3
Pages
320–324
Identifiers
PMID: 16200630
Source
Medline
License
Unknown

Abstract

APE is an efficacious regimen with minimal toxicity. Novel regimens are necessary to: (1) re-induce remission, (2) treat newly diagnosed patients, and (3) augment therapy in patients with slow response to standard regimens. This regimen had minimal toxicity and an excellent response rate that facilitated long term survival, often in conjunction with transplantation. The Children's Oncology Group is using a similar regimen to augment therapy for slow responders on a current Hodgkin disease trial.

Report this publication

Statistics

Seen <100 times